Systemic steroid treatment of grade I acute GVHD increases steroid-refractory GVHD and NRM
Year: 2026
Type: article
Abstract: = .026). MAGIC biomarkers identified most patients with grade I GVHD as low risk and unlikely to progress to severe GVHD regardless of treatment. Nevertheless, low-risk patients who received up-front steroids experienced a threefold increase in infectious deaths compared with those treated topically. This study supports the consensus recommendation of topical therapy for patients with low-risk grade I GVHD, a strategy that can be supported by biomarkers to avoid unnecessary steroid exposure and increased NRM.
Authors: Yu Akahoshi, Nikolaos Katsivelos, Ioannis E. Louloudis, Daniela Weber, Francis Ayuk, William J. Hogan, Yi-Bin Chen, Aaron M. Etra, Paibel Aguayo-Hiraldo, Chantiya Chanswangphuwana, Hannah K. Choe, Elizabeth O. Hexner, Carrie L. Kitko, Monzr M. Al Malki, Pietro Merli, Timothy S. Olson, Muna Qayed, Ingrid Vasova, Matthias Wölfl, Janna Baez, Gilbert Eng, Sigrun Gleich, George Morales, Nikolaos Spyrou, Rachel Young, Marcio Diniz, Ryotaro Nakamura, John E. Levine, James L. M. Ferrara
Institutions: Tisch Cancer Institute, National Cancer Center Hospital, Icahn School of Medicine at Mount Sinai, University of Regensburg, University Medical Center Hamburg-Eppendorf, Mayo Clinic, Massachusetts General Hospital, University of Southern California, Children's Hospital Los Angeles, Chulalongkorn University, King Chulalongkorn Memorial Hospital, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Abramson Cancer Center, University of Pennsylvania, Vanderbilt University Medical Center, City Of Hope National Medical Center, City of Hope, Bambino Gesù Children's Hospital, Children's Hospital of Philadelphia, Emory University, Friedrich-Alexander-Universität Erlangen-Nürnberg, Universitätsklinikum Erlangen, Universitätsklinikum Würzburg
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,000
Awards: G20952977, G4388466716
OpenAlex ID: W7140101896